SEC Form 4 · accession 0001179110-15-004455
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James DArecca
Officer — CHIEF ACCOUNTING OFFICER
Period of report
Mar 4, 2015
Accepted (ET)
Mar 6, 2015 · 5:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1,F2 | Mar 4, 2015 | A | 877 | $296.14 | A | 1,215 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $296.14 | Mar 4, 2015 | A | 1,169 | A | — | Mar 4, 2025 | Ordinary Shares | 1,169 | 1,169 | D |
Explanation of responses
- F1The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Actavis plc. The restricted share units will vest twenty-five percent (25%) on March 4, 2016, twenty-five percent (25%) on March 4, 2017, twenty-five percent (25%) on March 4, 2018 and twenty-five percent (25%) on March 4, 2019.
- F2Includes 1,215 restricted share units.
- F3The option will vest twenty-five percent (25%) on March 4, 2016, twenty-five percent (25%) on March 4, 2017, twenty-five percent (25%) on March 4, 2018 and twenty-five percent (25%) on March 4, 2019.